NASDAQ:MREO
Mereo BioPharma Group plc
Mereo BioPharma Group plc's revenue was $500,000 in fiscal 2025. Free cash flow was −$31.0M, −6198.2% of revenue, and the diluted share count rose 7.8%.Summary generated from Mereo BioPharma Group plc's SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$500,000
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−8021.4%
Net margin−8375.6%
ROICn/a
Return on equity−82.2%
Debt / equityn/a
Free cash flow−$31.0M
FCF margin−6198.2%
Share count change+7.8%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 10 | 0 | 1 |
| Operating income | −54 | −28 | −47 | −40 |
| Net income | −42 | −29 | −43 | −42 |
| Free cash flow | −49 | −21 | −33 | −31 |
Recent filings
- 8-KNotice of delisting or listing-rule failure
Aug 19, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KEntry into a material agreement
Aug 11, 2026 - 8-KResults of a shareholder vote
May 14, 2026 - 8-K/AAmended results of operations and financial condition
May 12, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KCompletion of an acquisition or disposition
May 12, 2026